This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

ThromboGenics Business Update H1 2013

LEUVEN, Belgium, August 29, 2013 /PRNewswire/ --

Conference call and webcast scheduled today at 06:30 PM CET - 12:30 PM EST

  • Total H1 2013 revenue amounted to €102.7 million
  • Profitable first half - net profit of €54.6 million
  • End of June 2013 cash position of €193.6 million
  • JETREA ®   launched in the US in mid-January: initial US sales H1 2013 (end of June) amounted to €12.5 million ( $US 16.6 million)
  • JETREA ®   approved in EU in March
  • JETREA ®   launched in April by partner Alcon (Novartis) in the EU - UK, Germany and Scandinavia
  • JETREA ®   received positive initial NICE recommendation for vitreomacular traction and macular hole
  • Germany's IQWiG confirmed JETREA ®   demonstrates major added value for the treatment of vitreomacular traction and macular hole
  • JETREA ®   received approval by Health Canada - first Rest of World (ROW)  and non-European market
  • Phase II trial with ocriplasmin in wet AMD patients showed a positive trend
  • Deal signed to build ophthalmology pipeline: Eleven Biotherapeutics - focus on diabetic macular edema

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today issues a business and financial update for the six months ending 30 June, 2013.

The first six months of 2013 have been significant in transforming ThromboGenics into an integrated biopharmaceutical company.

In mid-January, the Company launched its lead drug JETREA ® (ocriplasmin) in the US through its own commercial organization.

In April, its partner Alcon launched JETREA ® in Europe after it was approved by the European Commission in March 2013. In Europe the drug is now available in the UK, Germany and the Nordic region.

ThromboGenics received €90 million in milestone payments from Alcon for the EU approval and first European launch of Jetrea. This funding will enable ThromboGenics to invest in the further development of its ophthalmic franchise anchored by JETREA ®.

Earlier this month in August, ThromboGenics' JETREA ® also received approval from Health Canada for the treatment of symptomatic vitreomacular adhesion, heralding the first approval for its drug in a market outside the US and Europe.

JETREA ®is the first pharmacological treatment indicated for an important sight-threatening condition, symptomatic vitreomacular adhesion (VMA)/ vitreomacular traction (VMT) in the US and Europe respectively. VMT/ VMA is an age-related, progressive, sight-threatening condition that may lead to visual distortion, decreased visual acuity and central blindness.

Highlights (including post-period events):

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,856.78 -278.94 -1.54%
S&P 500 2,071.26 -29.78 -1.42%
NASDAQ 4,927.37 -55.4390 -1.11%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs